[1] 程敏,吴令英,章文华,等.215例老年宫颈癌的临床分析[J].中华肿瘤杂志,2009,31(5):388-391.
[2] COLEMAN C N,MINSKY B D.The verdict is in:the time for effective solutions to the global cancer burden is now[J].Lancet Oncol,2015,16(10):1146-1147.
[3] 郝敏,蔺莉.绝经后妇女宫颈上皮内瘤变Ⅱ级及以上患者临床特点分析[J].中国微创外科杂志,2017,17(2):155-158.
[4] 黄恩杰,罗新.中国大陆宫颈细胞学筛查技术实施的现状及缺憾[J].中国计划生育和妇产科,2016,8(9):4-7.
[5] 王爱春,顾依群,王军,等.TCT及HC2-HPV-DNA检测对绝经后妇女宫颈癌筛查的应用价值评估[J].现代肿瘤医学,2011,19(1):133-135.
[6] SANJOSE S D,QUINT W G,ALEMANY L,et al.Human papilloma-virus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J].Lancet Oncol,2010,11(11):1013-1014.
[7] 陈娟,麻全慧,施建丰,等.南京地区2387例有性生活女性的宫颈脱落细胞高危HPV检测分析[J].山东医药,2014,54(23):70-72.
[8] 孙静波,朱凤琴.宫颈人乳头瘤病毒联合液基细胞学检测在宫颈疾病筛查中的价值分析[J].安徽医药,2016,20(6):1119-1122.
[9] CHELMOW D.Cervical cancer screening and prevention[J].Obstet Gynecol,2016,127(1):1-20.
[10] 唐雪莲,梁绮文,王芳,等.深圳市社区妇女与妇科门诊患者宫颈癌认知及筛查情况调查[J].东南大学学报(医学版),2013,32(4):449-452.
[11] ELIT L.Role of cervical screening in older women[J].Maturitas,2014,79(4):413-420. |